Safety and Efficacy of Busulphan Based on Dosing Patterns in the Real‐World Management of Myeloproliferative Neoplasms
eJHaem · 2025-04 · 6 (2)
DOI: 10.1002/jha2.1097 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 19.03.2025. Verfasst von Ali Mahdi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology Aneurin Bevan University Health Board Newport UK. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Myeloproliferative neoplasms (MPNs), such as polycythaemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF), are primarily treated by managing blood counts to reduce the thrombotic risk using cytoreductive agents. Busulphan, an oral alkylating agent, has been historically used for MPN management due to its myelosuppressive effects, but concerns about its risk of leukaemic transformation have limited its use.
Methods
This real‐world retrospective study evaluated the safety and efficacy of busulphan in 115 MPN patients across 13 UK hospitals. Responses in patients with ET and PV only were assessed using European LeukemiaNet (ELN) criteria.
Results
With a median age of 78 years, the overall response rate was 78.1%, with 29% of PV and 18% of ET patients achieving complete responses. Dosing regimens were similarly distributed between repeated single doses of busulphan (31%), courses of treatment lasting 1–4 weeks (30%) and continuous therapy for more than 4 weeks (35%). No cases of disease progression to acute leukaemia or myelofibrosis were recorded during the median follow‐up of 23 months. Adverse events were infrequent, with fatigue and cytopaenia being the most common (4% each).
Conclusion
Busulphan demonstrated a favourable safety profile and is a viable cytoreductive option, particularly for elderly patients who are intolerant to hydroxycarbamide. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Haematology Aneurin Bevan University Health Board Newport UK.
- Department of Haematology University College London Hospital NHS Foundation Trust London UK.
- Department of Haematology Torbay and South Devon NHS Foundation Trust Torquay UK.
- Department of Haematology Gloucestershire Hospitals NHS Trust Gloucester UK.
- Department of Haematology Royal Cornwall Hospital NHS Trust Truro UK.
- Department of Haematology Musgrove Park Hospital NHS Trust Taunton UK.
ORCID-Profile: Ali Mahdi, Alexandros Rampotas
Zitieren
APA
Mahdi, A., Rampotas, A., Roberts, P., Stokes, J., Mahdi, E., Witherall, R., Mannari, D., Ibrahim, N., Naylor, G., Garg, M., Manjra, I., Glancy, P., Katis, G., Bhagat, S., Coppell, J., McGregor, A., Frewin, R., & Butt, N. M. (2025). Safety and Efficacy of Busulphan Based on Dosing Patterns in the Real‐World Management of Myeloproliferative Neoplasms. eJHaem, 6(2). https://doi.org/10.1002/jha2.1097
Vancouver
Mahdi A, Rampotas A, Roberts P, Stokes J, Mahdi E, Witherall R, et al. Safety and Efficacy of Busulphan Based on Dosing Patterns in the Real‐World Management of Myeloproliferative Neoplasms. eJHaem. 2025;6(2). doi:10.1002/jha2.1097
BibTeX
@article{Mahdi2025,
author = {Mahdi, Ali and Rampotas, Alexandros and Roberts, Patrick and Stokes, Joanna and Mahdi, Eamon and Witherall, Ruth and Mannari, Deepak and Ibrahim, Naheed and Naylor, Georgina and Garg, Mamta and Manjra, Imran and Glancy, Paula and Katis, George and Bhagat, Sahil and Coppell, Jason and McGregor, Andrew and Frewin, Rebecca and Butt, Nauman M},
title = {Safety and Efficacy of Busulphan Based on Dosing Patterns in the Real‐World Management of Myeloproliferative Neoplasms},
journal = {eJHaem},
year = {2025},
volume = {6},
number = {2},
doi = {10.1002/jha2.1097}
}
EUVIMED